Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Barcelona – page 170

3 147 clinical trials in Barcelona, Spain across 23 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Barcelona at a glance
3 147
clinical trials
  • Research sites23
Type of trial
Recruitment status
Quick filters

3 147 trials in Barcelona

Open in trial search

Plasma cell myeloma

Not recruiting

Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

HIV infection

Not recruiting

Study Comparing DTG/3TC and BIC/FTC/TAF for Maintaining HIV Control in Adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Fundacion Seimc Gesida

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Not recruiting

Study of Tirzepatide for Reducing Obesity and Related Health Issues in Adolescents

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Uveal melanoma

Not recruiting

Study of AloCelyvir for Patients with Metastatic Uveal Melanoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Neovascular age-related macular degeneration

Not recruiting

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Opthea Limited

Myasthenia gravis

Not recruiting

Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Infertility

Not recruiting

Study on the Effect of Ovarian Stimulation Intensity Using Clomifene Citrate and Follitropin Alfa in Women with Infertility and Suboptimal Response

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Clomifene Citrate
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Multiple system atrophy

Not recruiting

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Barcelona

What the registry says about research in the country

01 Neurodegenerative Research

Innovative studies focusing on Alzheimer's Disease and Frontotemporal Dementia, utilizing advanced brain imaging techniques to track disease progression and evaluate new therapeutic approaches.

  • Cerebral tau aggregates assessment
  • Amyloid deposition tracking
  • Progressive supranuclear palsy research

Advanced neuroimaging studies using PET tracers to understand disease mechanisms.

02 Infectious Disease Prevention

Comprehensive vaccine trials targeting various infections including respiratory syncytial virus, Cytomegalovirus, and Herpes Zoster.

  • RSV vaccine development for older adults
  • CMV prevention studies
  • COVID-19 booster research

Focus on developing effective immunization strategies for vulnerable populations.

03 Metabolic and Chronic Conditions

Research examining treatments for Type 1 Diabetes and obesity, alongside studies in bladder cancer and urinary tract infections.

  • Diabetes management therapies
  • Cancer immunotherapy trials
  • UTI vaccine development

Innovative approaches to chronic disease management and prevention.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.